

Spring Group Meeting

# San Francisco Specials

APRIL 30 - MAY 2, 2026



Genitourinary Committee

# Genitourinary Committee

## Leadership

Chair: ..... Seth P. Lerner, MD  
 Vice-Chair: ..... Daniel P. Petrylak, MD  
 Chair Emeritus: ..... Ian M. Thompson, Jr., MD  
 Executive Officer: ..... Neeraj Agarwal, MD  
 Statisticians: ..... Cathy M. Tangen, DrPH  
 ..... Melissa Plets, MS  
 ..... Sam Callis, MS  
 ..... Gabby Lopez, MS  
 ..... Sara Threlkel, BS

## Scientific Leadership

Translational Medicine: ..... Joshua J. Meeks, MD, PhD (GU Chair)  
 ..... Roger Li, MD (Bladder)  
 ..... Amir Goldkorn, MD (Prostate)  
 ..... Sumanta “Monty” K. Pal, MD (Renal)  
 Radiation Oncology: ..... James B. Yu, MD  
 ..... Daniel A. Hamstra, MD  
 Imaging: ..... Evan Y. Yu, MD  
 ..... Hiram Shaish, MD  
 ..... John D. Hazle, PhD  
 Immunotherapeutics: ..... Shuchi Gulati, MD (Medical Onc)  
 ..... Robert Svatek, MD (Urologic Onc)  
 Pathology: ..... M. Scott Lucia, MD  
 Surgery: ..... Kelly L. Stratton, MD  
 Early Therapeutics: ..... Parminder Singh, MD  
 Bladder Organ Site Chairs: ..... Siamak Daneshmand, MD (Localized)  
 ..... Thomas W. Flaig, MD (Advanced)  
 Prostate Organ Site Chairs: ..... Daniel W. Lin, MD (Localized)  
 ..... Tanya B. Dorff, MD (Advanced)  
 Renal Organ Site Chairs: ..... Brian Shuch, MD (Localized)  
 ..... Ulka N. Vaishampayan, MD (Advanced)

## Designates

Cancer Control: ..... Clara Hwang, MD  
 ..... Sarah P. Psutka, MD, MSC  
 Accrual Champion: ..... Jessica D. McDermott, MD  
 NCORP: ..... Scott Edward Delacroix, Jr., MD  
 ..... Helen Heng-Shan Moon, MD  
 Veterans Affairs: ..... Michael M. Goodman, MD  
 ..... Aihua Edward Yen, MD  
 Data Coordinators: ..... Laura Wells, BA  
 ..... Tonya Johnson, BS  
 ..... Michele Counts, BS  
 Oncology Research Professionals: ..... Abigail L. Cornette, MS  
 ..... Gary Lee Duvall, RN

Patient Advocates: ..... Darrell Nakagawa (Bladder)  
 ..... Joël R. Pointon, MPH (Prostate)  
 ..... Laura B. Esfeller, MA (Renal)  
 Pharmaceutical Science: ..... Stephanie Elise Trexler, Pharm D  
 Senior Protocol Project Manager: ..... Megan Keim  
 Clinical Trials Program Manager: ..... Sarah Cantu

## Time/Location

Saturday, May 2, 2026 9:15 a.m. - 11:15 a.m.  
 Room: Grand Ballroom A (Street Level)

## Agenda

9:15 - 9:30 am: Chair’s Welcome and Opening Remarks - Seth Lerner  
 9:30 - 9:55 am: Cancer Control - Clara Hwang and Sarah Psutka  
 9:55 - 11:15 am: Review of open approved trials - all organ site chairs

Prostate – Dan Lin and Tanya Dorff  
 Renal – Brian Shuch and Ulka Vaishampayan  
 Bladder – Sia Daneshmand and Tom Flaig

## Cancer Control

Organ Site Chairs: Drs. Clara Hwang and Dr. Sarah Psutka

## Active Studies

**S1600**, “A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes.” Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19. Closed to Accrual and Treatment 10/20/23.

**S1823**, “A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors”, PI: Craig Nichols– Activated 6/1/20. Closed to Accrual 5/20/24. GU Champions: Thomas Frye & Anishka D’Souza

**S1931 (Companion Study)**: Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer. PI: Cristiane Bergerot.

**S1937 (Companion Study)**: Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937.

# Genitourinary Committee

## Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

### Priority Study

**S2210**, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Activated 8/14/23. Temporarily Closed to Accrual 1/22/26.

### Active Studies

**S2312**, "A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature." Dr. Paul Corn. Activated 9/3/24. Revision #1 released 1/15/26.

**S1802**, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18. Revision #5 released 8/15/24.

**CTSU/A031102**, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15. Closed to Accrual 10/26/22.

**CTSU/EA8171**, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18. Closed to Accrual 2/28/25.

**CTSU/EA8184**, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21. Closed to Accrual 6/26/25.

**CTSU/EA8191**, "Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE)." Dr. N. Vapiwala. Activated: 10/8/2020. Arms A & B Closed to Accrual 1/31/25.

**CTSU/NRG-GU002**, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16. Closed to Accrual 9/6/22.

**CTSU/NRG-GU008**, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE\*) \*Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

**CTSU/NRG-GU009**, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT\*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21. Closed to Accrual 8/18/25.

**CTSU/NRGGU010**, "Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)." Drs. N Desai and A. Berlin. Activated: 11/3/21. Groups 3 and 4 Closed to Accrual 11/22/24.

**CTSU/NRGGU011**, "A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadioTherapy with or Without ANDrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)." Dr. B. Koontz.

### Closed Studies

**S1216**, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17. All participants off of treatment and follow up by 7/15/25. FDAAA/IRB Completed.

**CTSU/NRG-GU005**, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22. Closed to Accrual and Treatment 6/8/22.

**CTSU/NRG-GU006**, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

**CTSU/RTOG-0924**, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial." Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

# Genitourinary Committee

**CTSU/NRG-GU007**, “Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR\*) \*Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I).” Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/22.

**CTSU/EA8153**, “Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial.” Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

**CTSU/AGCT1531**, “A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.” Dr. A. D’Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21. Stratum 2 Temporarily Closed to Accrual as of 12/17/24. AYA-HEARS Ototoxicity PRO Study Temporarily Closed to Accrual as of 02/12/21.

## Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

## Priority Study

**S1931**, “Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial).” Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20. Revision #10 released on 2/2/26.

## Concepts in Development

**S2419**, “Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial].” Drs. P. Barata and U. Vaishampayan. Under CIRB initial review as of 2/5/26. Target activation 4/1/26.

## Active Studies

**CTSU/AREN1721**, “A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups.” Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22. Closed to Accrual 3/24/23.

**CTSU/A031704**, “PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE].” Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21. Closed to Accrual 5/15/24.

**CTSU/A031801**, “A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical).” Dr. M. Parikh. Activated: 12/13/19. Closed to Accrual 12/19/25.

**CTSU/A031901**, “Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial.” Dr. D. Vaena. Activated: 12/10/20. Closed to Accrual 11/29/22.

## Closed Studies

**S1500**, “A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET).” Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently Closed: 12/15/19.

**S0931**, “EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.” Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

**S2200**, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)” Drs. B. Maughan and S. Pal. Activated 9/19/22. Temporarily closed to accrual 1/17/26. Permanently Closed: 3/1/26.

**CTSU/E2810**, “Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.” Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

**CTSU/A031501**, “Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation.” Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

**CTSU/EA8143**, “A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC).” Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

# Genitourinary Committee

## Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak Daneshmand (Local).

### Priority Study

**S1937**, “A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.” Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23. Re-opened Arms 1&3 to accrual and permanently closed Arm 2 on 2/15/24. Revision #4 had Sacituzumab govitecan removed as a treatment option on 2/3/25.

### Concepts in Development

**S2611**, “A Randomized Comparison of Intravesical Therapies (ARCIS): A randomized phase III study of intravesical gemcitabine and docetaxel (GEM-DOCE) versus intravesical cimetidine, methotrexate, and gemcitabine (CRETO-GEM) for the treatment of bacille Calmette-Guérin (BCG)-unresponsive and BCG-exposed non-muscle invasive bladder cancer (NMIBC).” Dr. M. Tyson. Reviewed by the GU Steering Committee on 1/21/2026, received “pending” decision. Concept withdrawn from GUSC. Plan to resubmit to GUSC on 4/22 for May review date.

### Active Studies

**S2427**, “Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (BRIGHT).” Dr. L. Ballas. Activated 9/4/25. Revision #1 released 1/15/26.

**CTS/A031701**, “A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.” Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

**CTS/A031803**, “Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20. Closed to accrual: 7/23/25.

**CTS/EA8185**, “Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE).” Drs. T. Mitin and J. Meeks. Activated: 8/25/20. Closed to accrual: 10/2/23.

**CTS/EA8192**, “A Phase II/III Trial of MEDI4736 (Durvalumab) and

Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy” Drs. S. Psutka and A. Tripathi. Activated: 5/6/21. Arm C Closed to Accrual as of 4/25/25.

### Closed Studies

**S1011**, “A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.” Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17. Listed as FDAAA/IRB Completed on 1/8/25.

**S1602**, “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer.” Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/20.

**S1605**, “Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19. FDAAA/IRB Completed.

**S2011**, “Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma.” Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Closed to Accrual: 11/15/23. Administratively Complete.

**S1806**, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19. Step 1 accrual closed 3/1/24. Revision #10 released 8/15/2025. Closed to accrual and treatment: 4/1/24.

## Translational Medicine

Chair: Dr. Joshua Meeks

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. David Braun

## Diverse Studies of Interest

**S1609**, “DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.” Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51. Closed to Accrual 3/15/2023.

# Genitourinary Committee

**CTSUA031702**, “A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)” Dr. S. Liu. Activated: 4/12/19; Open Cohorts: A, C, D, J, H, L. Temporarily Closed Cohorts: B, E, F, G, I, K.

**CTSUEAY 131**, “Molecular Analysis for Therapy Choice (MATCH).” Dr. V. Villalobos. Activated: 8/12/15; Closed to Accrual 12/23/2022.

**CTSUEA8134**, “InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study).” Dr. C. Pettaway. Activated: 9/8/17.

## Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

## Published/Accepted Manuscripts

**S2210** Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations. Heather H Cheng, Sam Callis, Evan Y Yu, Scott E Delacroix, Alexandra O Sokolova, Catherine M Tangen, Seth P Lerner, Tanya Barauskas Dorff, Daniel W Lin. *Eur Urol Focus*. 2025 Dec 6:S2405-4569(25)00343-8. doi: 10.1016/j.euf.2025.11.011. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/41354605/>

**Multiple Studies** Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer. Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, Leslie Ballas, Rick Bangs, Kenneth Brothers, Stephanie Cooper Greenberg, Scott Delacroix, James J Dignam, Jason A Efstathiou, Adam S Feldman, Jared C Foster, Noah M Hahn, Emma Hall, Donna E Hansel, Jean Hoffman-Censits, Ashish M Kamat, Sophia C Kamran, Francesca Khani, Seth P Lerner, Robert Lipman, Bhupinder Mann, David McConkey, James McKiernan, Tracy L Rose, Angela B Smith, Catherine Tangen, Abdul Tawab Amiri, Chana Weinstock, Pamela J West, Matthew I Milowsky, Peter C Black. *Bladder Cancer*. 2025 Feb 24;11(1):23523735251319185. doi: 10.1177/23523735251319185. eCollection 2025 Jan-Mar. [S1605, S1806] <https://pubmed.ncbi.nlm.nih.gov/40034245/>

**A031501** Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. A Apolo, K Ballman, G Sonpavde, S Berg, W Kim, R Parikh, M Teo, R Sweis, D Geynisman, P Grivas, G Chatta, J Kim, M Bilen, B McGregor, P Singh, A Tripathi, S Cole, N Simon, S Niglio, L Ley, L Cordes, S Srinivas, J Huang, P Steen, M Odegaard, C Watt, D Petrylak, J Hoffman-Censits, Y Wen, O Hahn, C Mitchell, A Tan, H Streicher, E Sharon, H Moon, M Woods, S Halabi, G Burbano, M Morris, J Rosenberg. *N Engl J Med*. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15. NIHMS2021479. <https://pubmed.ncbi.nlm.nih.gov/39282902/>

**C90203/S9921** Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer. Trevor C Hunt, Kamil Malshy, Matthew Steidle, Ashley Li, Jason Fairbourn, Zijiang Cheng, Jathin Bandari. *Prostate*. 2025 Dec;85(16):1522-1530. doi: 10.1002/pros.70043. Epub 2025 Sep 9. <https://pubmed.ncbi.nlm.nih.gov/40926427/>

## Submitted Manuscripts

**S1216** Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216). S Ingles, J Pinski, Z Manojlovic, S Xiong, D Weisenberger, A Goldkorn, C Tangen, D McConkey, P Lara, M Hussain, D Quinn, I Thompson, S Lerner, T Dorff, N Agarwal. Submitted 2025.

**S9346** Evaluating Survival Post-7-Month PSA Response, Stratified by Response, Disease Extent, and Intermittent vs. Continuous ADT in Metastatic Hormone-Sensitive Prostate Cancer: The S9346 Trial. A Sokolova, C Tangen, M Hussain, C Sweeney, T Dorff, M Ong, U Swami, N Aggarwal, I Thompson, S Lerner. Submitted.

**Multiple Studies** Practice Patterns in Metastatic Hormone-Sensitive Prostate Cancer: A Survey of North American Cooperative Group Oncologists. P Breen, C Chalker, M Ong, O Anya, R McKay, M Carducci, C Kyriakopoulos, M Schweizer, N Haas, A Mandl, C Tangen, S Gulati, M Keim, S Lerner, C Ryan, R Ng, T Dorff, A Sokolova. Submitted.

**S1314** Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner. A Zadoroznyj, P Eriksson, C Bernardo, L Tran, C-A Mattsson, T Flaig, C Tangen, S Lerner, D McConkey, M Höglund, F Liedberg, G Sjödaahl. Submitted.

## Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1802	S1931	S1937	S2200	S2210	S2312	S2427	A021804
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	7	1	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	2	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	6	-	1	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	1	1	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	-	-	-	1	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	3	-	1	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	11	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	4	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	5	3	-	7	1	1	-	-
Columbia University Minority Underserved NCORP	2	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	-	5	-	-	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-	-	-
Desert Regional Medical Center	2	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	26	-	-	-	3	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	6	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	83	3	2	1	1	-	-	-
Hartford Hospital	-	-	-	-	-	1	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	11	1	-	3	-	1	-	-
Henry Ford Hospital	31	-	4	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	8	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	41	-	-	-	-	-	-	-
Intermountain Medical Center	2	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	19	2	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-
Loyola University Medical Center	9	1	2	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	8	-	3	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	15	-	4	2	-	4	-	-
Montana Cancer Consortium NCORP	5	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	12	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-

## Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1802	S1931	S1937	S2200	S2210	S2312	S2427	A021804
New Mexico Minority Underserved NCORP	-	2	1	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	1	1	1	-	2	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	-	-	-	-	-	-	-
Oregon Health and Science University	-	3	3	1	1	-	-	1
Regents of the University of Michigan	2	27	2	-	-	-	-	-
Rhode Island Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	9	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	5	-	-	-	-	-
Tulane University School of Medicine	-	9	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	17	4	5	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	9	-	3	-	-	-	-	-
UC San Diego Moores Cancer Center	7	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	4	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	4	2	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	9	2	17	-	-	-	-	-
U Alabama at Birmingham / Deep South Research Consortium LAPS	-	7	-	-	-	-	-	-
University of Arkansas for Medical Sciences	9	-	-	1	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	8	3	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	10	-	10	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	-	3	-	-	-	-	-
University of Kentucky/Markey Cancer Center	2	-	1	-	-	-	-	-
University of Mississippi Medical Center	1	-	1	1	-	-	-	-
University of Nebraska Medical Center	7	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	47	6	8	3	-	5	-	-
University of Rochester LAPS	26	3	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	2	7	-	-	-	1	-	-
University of Texas MD Anderson Cancer Center LAPS	88	-	-	-	-	10	-	-
University of Utah - Huntsman Cancer Institute LAPS	19	2	4	3	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	3	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	8	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	15	1	1	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	-	3	-	-	-	-	-
ALLIANCE	122	8	7	2	-	6	-	-
ECOG-ACRIN	106	17	21	6	-	4	1	-
NRG	120	16	2	4	-	-	-	-
<b>Total</b>	<b>990</b>	<b>145</b>	<b>123</b>	<b>35</b>	<b>6</b>	<b>37</b>	<b>1</b>	<b>1</b>

## Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A031701	A031702	A031801	A031803	A032102	A032103	A032201	CCTG-PR26
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	2	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	2	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	6	-	3	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	1	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	1	16	-	-	-	-
Hartford Hospital	1	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	2	-	-	-	-	-	-	-
Henry Ford Hospital	-	2	-	-	-	1	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	7	-	-	-	-	1	-
Loyola University Medical Center	-	1	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	1	-	-	-	-	-	-

## Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A031701	A031702	A031801	A031803	A032102	A032103	A032201	CCTG-PR26
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	6	-	-	-	7	2	1
Regents of the University of Michigan	-	-	-	-	-	3	-	-
Rhode Island Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	11	-	7	5	2	2	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	2	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	5	-	-	-	-	-	-
U Alabama at Birmingham / Deep South Research Consortium LAPS	-	1	1	12	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	1	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	2	-	-
University of Mississippi Medical Center	-	1	-	-	-	2	-	-
University of Nebraska Medical Center	-	-	-	-	-	2	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	1	-	-
University of Rochester LAPS	2	3	-	-	-	5	-	-
University of Texas Health Science Center at San Antonio	-	-	-	6	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	6	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-
<b>Total</b>	<b>28</b>	<b>28</b>	<b>15</b>	<b>47</b>	<b>2</b>	<b>32</b>	<b>5</b>	<b>1</b>

## Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008	NRGGU009	NRGGU010
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	4
Audie L Murphy VA Hospital	-	49	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	26	-	1	3
Banner University Medical Center - Tucson	-	-	-	-	-	-	1	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	29	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	1	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	33	-	16	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	11	-	-	71	6	16	6
Hartford Hospital	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	2	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	1	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	2	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	2	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	3
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	6	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	3	-	17	-	-	1
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	2	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	1	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-

## Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008	NRGGU009	NRGGU010
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	4	20	3
Northwestern University LAPS	-	-	-	-	-	-	-	4
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	15	18	-	32	-	-	-
Regents of the University of Michigan	-	-	-	-	-	-	-	1
Rhode Island Hospital	-	-	-	-	-	-	1	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	6	11
The West Clinic - Wolf River	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	4	-	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	3	-	-
UC San Diego Moores Cancer Center	-	-	1	-	5	-	2	2
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	18	-	-	-	20	-	-	-
U Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	3	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	-	2	-	-	17	13
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	3	11	7
University of Kentucky/Markey Cancer Center	-	-	-	4	15	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	2	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	6	-	7	-	4	4
University of Rochester LAPS	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	13	2	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	9	-	4	4
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	2	1
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-
<b>Total</b>	<b>25</b>	<b>91</b>	<b>66</b>	<b>6</b>	<b>260</b>	<b>16</b>	<b>89</b>	<b>67</b>

## Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGGU011	NRGGU012	NRGGU013
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-
Audie L Murphy VA Hospital	-	-	-
Banner MD Anderson Cancer Center	-	-	-
Banner University Medical Center - Tucson	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-
Cedars-Sinai Medical Center	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-
Columbia University Minority Underserved NCORP	-	-	-
CommonSpirit Health Research Institute	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-
Desert Regional Medical Center	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	1
Fred Hutchinson Cancer Research Center LAPS	7	-	7
Georgia Cares Minority Underserved NCORP	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-
Gulf South Minority Underserved NCORP	5	2	-
Hartford Hospital	-	-	-
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Houston Methodist Hospital	-	-	-
Instituto Nacional De Cancerologia	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-
Intermountain Medical Center	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-
Lahey Hospital and Medical Center	-	-	-
Loyola University Medical Center	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-
Montana Cancer Consortium NCORP	-	-	-
Mount Sinai Hospital	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-

## Genitourinary Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGGU011	NRGGU012	NRGGU013
New Mexico Minority Underserved NCORP	-	-	-
Northwell Health NCORP	-	-	-
Northwestern University LAPS	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	6	-	-
Regents of the University of Michigan	-	-	-
Rhode Island Hospital	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
Sutter Cancer Research Consortium	3	1	-
The West Clinic - Wolf River	-	-	-
Tulane University School of Medicine	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-
UC San Diego Moores Cancer Center	-	3	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-
U Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-
University of Colorado Cancer Center LAPS	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-
University of Mississippi Medical Center	-	-	-
University of Nebraska Medical Center	-	2	-
University of Oklahoma Health Sciences Center LAPS	-	2	5
University of Rochester LAPS	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-
Virginia Mason Medical Center	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-
Western States Cancer Research NCORP	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
<b>Total</b>	<b>23</b>	<b>10</b>	<b>13</b>

